Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau

Recurrent ovarian cancer (OvCa) is thought to result in part from the inability to eliminate rare quiescent cancer stem cells (CSCs) that survive cytotoxic chemotherapy and drive tumor resurgence. The Sialyl-Thomsen-nouveau antigen (STn) is a carbohydrate moiety present on protein markers of CSCs in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Starbuck, Kristen, Al-Alem, Linah, Eavarone, David A., Hernandez, Silvia Fatima, Bellio, Chiara, Prendergast, Jillian M., Stein, Jenna, Dransfield, Daniel T., Zarrella, Bianca, Growdon, Whitfield B., Behrens, Jeff, Foster, Rosemary, Rueda, Bo R.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955411/
https://ncbi.nlm.nih.gov/pubmed/29796189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25289
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars